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Abstract
Ceramides are important intracellular second messengers that play a role in the regulation of cell growth, differentiation, and
programmed cell death. To determine whether ceramides can mediate the apoptosis of HCT116 and OVCAR-3 cancer cells, exogenous
C2-, C6-, and C16-ceramides were used to mimic the endogenous lipid increase that follows a large variety of stresses. C2- and C6-
ceramides (cell-permeable ceramide analogs), but not C16-ceramide, induced nuclear factor-kB (NF-kB) DNA-binding, caspase-3
activation, poly(ADP-ribose) polymerase degradation, and mitochondrial cytochrome c release, indicating that apoptosis occurs through
the caspase cascade and the mitochondrial pathway. No difference in survival was observed between control cells and cells expressing
mutated IkBa and treated with the permeable ceramides. This suggests that, at least in these cell lines, stable NF-kB inhibition did not
modify the ceramide-induced cytotoxicity pathway. C6-ceramide also induced a double block in G1 and G2, thus emptying the S phase.
# 2003 Elsevier Science Inc. All rights reserved.
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1. Introduction
The sphingomyelin pathway is a ubiquitous signaling
system that links specific cell-surface receptors and dif-
ferent types of physical stress to the nucleus [1–3]. This
pathway is initiated by the hydrolysis of membrane phos-
pholipid sphingomyelin to ceramide, which results from
the activation of sphingomyelin-specific forms of phos-
pholipase C called sphingomyelinases. Ceramides are also
generated by another mechanism involving ceramide
synthase. Structurally, the ceramides exhibit a long amino
alcoholic chain covalently bound via an amide linkage to a
fatty acyl moiety that can vary in length (synthetic short
chain ceramides: C2-, C4-, C6-, . . . or natural ceramides:
C16-, C18-, C20-, . . .) [4].
Ceramides are produced in response to a large variety of
stresses that mediate growth arrest, differentiation, senes-
cence, apoptosis, or immune response [5,6]. The wide
range of biological effects mediated by ceramides depends
on many parameters, such as the cell type, the nature of the
cell receptors expressed, and their concentration, suggest-
ing the existence of multiple downstream targets activated
through distinct intracellular pathways.
One of the most clearly illustrated targets of ceramides is
cell death [7–15]. Interestingly, ceramides induce not only
apoptosis, but also caspase-independent and/or non-apop-
totic cell death, depending on the cell type. Recent data
demonstrate that ceramides play an important role in one or
several stages of apoptosis. Indeed, several cytokines and
environment stresses known to initiate apoptosis, including
TNF-a, CD95/Fas/APO-1, chemotherapeutic drugs, ioniz-
ing radiations, ultraviolet radiation, heat shock, and oxi-
dative stress, appear to induce a rapid rise of intracellular
ceramide concentration [9,11,15–17].
The mechanism by which ceramides mediate apoptosis
has not been fully addressed yet, although mitochondria
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are known to be a target for ceramides. Recent studies have
demonstrated that exogenous ceramides can induce the
alteration of mitochondrial calcium homeostasis [18].
Moreover, C2-ceramide has been reported to increase
the permeability of mitochondrial membranes and to
decrease the membrane potential [19]. Ceramides also
mediate apoptosis in HL-60 cells through mitochondrial
signaling, which involves translocation of Bax to mito-
chondria where it promotes the release of cytochrome c
[20].
However, it is still unknown whether ceramides are
essential for the initiation or for the execution of apoptosis
[7,12,21]. The clarification of the role of ceramides in
apoptosis may provide further insights into the treatment of
several human diseases, such as cancer. Indeed, recent
reports have shown that ceramide-dependent stress signal-
ing is associated with chemotherapeutic agents known to
trigger apoptosis. It is not entirely clear, however, what step
of the transduction pathway leading to apoptosis is influ-
enced or dependent upon ceramide generation [8,22].
It has been reported that the addition of exogenous
sphingomyelinase or ceramide induces NF-kB activation
[23]. NF-kB is a rapidly inducible transcription factor,
activated by a number of external or internal stimuli, such
as cytokines, chemotherapeutic agents, or radiation. NF-kB
can protect several cell types against apoptosis, suggesting
that it can participate in resistance to cancer treatment.
However, in our experience, the inhibition of NF-kB activ-
ity in several cancer cell lines has a variable effect on cell
mortality, depending on the cell type, the stimulus, and the
level of NF-kB inhibition (for a review, see Ref. [24]).
Moreover, in some experimental systems, NF-kB activation
is required for the onset of apoptosis [25].
Ceramides have also been shown to play a role in growth
arrest at the G0/G1 phase of the cell cycle in response to
serum withdrawal. For instance, Molt-4 leukaemia cells
treated with C6-ceramide undergo a G0/G1 cell cycle
arrest [26].
In the present study, we demonstrated that the C2- and
C6-ceramides induce NF-kB activation, caspase-3 activity,
PARP cleavage, and mitochondrial cytochrome c release in
human colon carcinoma cells (HCT116) and in ovarian
carcinoma cells (OVCAR-3). Exogenous C16-ceramide,
which likely does not penetrate into the cell, had no effect.
These results suggest that permeable ceramide-induced
apoptosis involves mitochondria effectors and caspase
activity. In addition, the role of ceramide in cell cycle
arrest has been investigated.
2. Materials and methods
2.1. Cell culture and biological reagents
HCT116 human colon carcinoma cells (ATCC CCL
247) were cultured in McCoy’s 5A modified medium (Life
Technologies, Inc.) supplemented with 10% fetal bovine
serum, 1% L-glutamine (200 mM), 100 units/mL of peni-
cillin, and 100 mg/mL of streptomycin. OVCAR-3 ovarian
carcinoma cells were maintained in RPMI 1640 medium
(Life Technologies) supplemented with 10% fetal bovine
serum, 1% L-glutamine (200 mM), 100 units/mL of peni-
cillin, and 100 mg/mL of streptomycin. The cells were
maintained at 378 in a 5% CO2 atmosphere.
HCT116-MT and OVCAR-3-MT cells were stably
transfected with an expressing vector coding for an IkBa
protein mutated at serines 32 and 36 and cultivated in the
presence of geneticin (500 mg/mL, G418 active concentra-
tion; Roche) [27].
C2-, C6-, and C16-ceramides were obtained from San-
ver Tech (Boechout) and were solubilized in ethanol.
The human recombinant TNF-a (specific activity
>1:0 108 units/mg) was purchased from Roche. The
caspase inhibitor Z-VAD-fmk and the caspase-3 inhibitor
(Ac-DMQD-CHO) (Calbiochem) were added 1 hr before
treatment with ceramides.
2.2. EMSA
EMSA and supershifting analysis were performed as
described previously [28]. The palindromic (PD)-kB probe
was 50-TTGGCAACGGCAGGGGAATTCCCCTCTCCT-
TAGGTT-30. For supershifting experiments, 1 mL of the
antibody was preincubated at 48 with the extracts for
30 min before the addition of the labeled kB probe. The
antibody directed against an amino-terminal peptide of
p50, the antibody directed against the N-terminal 14 amino
acids after the methionine of p65, and the p52 monoclonal
antibody were purchased from Upstate Biotechnology. The
anti-RelB and the c-Rel antibodies were purchased from
Santa Cruz Biotechnology.
2.3. Determination of cellular viability
Stably transfected cells or untransfected cells were
seeded at a concentration of 104/well in flat-bottomed
96-well plates in 0.2 mL of medium. After 24 or 48 hr
of incubation in the presence of ceramide, cell viability was
measured by a colorimetric assay at 450 nm, based on the
cleavage of the tetrazolium salt WST-1 by mitochondrial
dehydrogenases in viable cells (cell proliferation reagent
WST-1; Roche).
2.4. Protein extraction and western blot analysis
Nuclear, cytoplasmic, and total protein extracts were
prepared as previously described [29]. Protein amounts
were quantified with the micro BCA Protein Assay
Reagent kit (Pierce).
Analysis of PARP cleavage was assessed by western blot
analysis. Briefly, extracts of 20 mg of protein were run on
10% SDS–polyacrylamide gels, transferred, and incubated
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with an anti-PARP-specific monoclonal antibody (Santa
Cruz Biotechnology) (1:5000), followed by a goat anti-
mouse-specific antibody (1:5000), and developed using
enhanced chemiluminescent detection methods (ECL Kit;
Amersham Pharmacia Biotech). Analysis of caspase-3 was
performed with an anti-caspase-3 monoclonal antibody (1/
2000) (Alexis). Detection of caspase-9 and cytochrome c
proteins was performed with an anti-caspase-9 polyclonal
antibody (1/2000) and an anti-cytochrome c monoclonal
antibody (1/500) (Pharmigen), respectively.
2.5. Caspase-3 activity assay
Cells were washed two times with PBS, lysed at 48 in
buffer A (1% Nonidet P-40, 20 mM Tris, 137 mM NaCl,
10% glycerol at pH 8), in the presence of 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 1 mM orthovanadate
sodium, and protease inhibitors (Complete; Roche), and
then centrifuged at 300 g for 5 min at 48. Fifty micrograms
of protein was incubated for 4 hr in the dark with 150 mL of
buffer A containing a 20 mM concentration of a caspase-3
substrate (acetyl-Asp-Glu-Val-Asp-amino-4-methylcou-
marin; Calbiochem).
Caspase-3 activity was determined by the amount of
released fluorescent product (coumarin), measuring emis-
sion at 460 nm with 380 nm excitation.
2.6. Flow cytometry analysis
Cells were washed in PBS, harvested after trypsin
treatment, and washed again in PBS. The pellets were
stained with propidium iodide and fluorescein isothiocya-
nate (FITC)-conjugated Annexin V as described by the
manufacturer (Annexin-V-FLUOS Staining Kit; Roche).
For cell cycle analysis, cells were prepared as described
by the manufacturer (Cycle Test Plus DNA reagent kit;
Becton Dickinson). A FACStar Plus flow cytometer (Bec-
ton Dickinson) with a 488 nm line 100 mW air-cooled
argon laser (Spinnaker 1161; Spectra Physics) and Cell
Quest software (Macintosh, Facstation; Becton Dickinson)
were used for the analysis. DNA histograms were analyzed
with ModFit software (Verity software).
2.7. Preparation of cytosolic protein extracts
To evaluate mitochondrial cytochrome c release, cyto-
solic protein extracts were prepared. Briefly, cells were
washed twice with PBS, and pellets were resuspended in
ice-cold buffer containing 20 mM HEPES, pH 7.5, 10 mM
KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM sodium
EGTA, 1 mM dithiothreitol, and 1 mM PMSF. Cells were
disrupted by 12 runs through a Dounce homogenizer.
Lysates were centrifuged at 10,000 g for 10 min and the
resulting supernatants were further centrifuged at
100,000 g for 1 hr at room temperature in a Beckman
TLX ultracentrifuge (Beckman).
2.8. Clonogenic survival assay
Cells were seeded in six-well plates at a concentration of
30,000/well and were treated with ceramide at different
concentrations (10, 25, and 50 mM) for 24 and 48 hr. Cells
were then washed and incubated with fresh medium for 12
days. The number of colonies (50 cells) was counted
after staining with crystal violet (1%, v/v).
2.9. Determination of apoptosis by cytochemical staining
The presence of apoptotic cells was determined by
fluorescent microscopy. Cells were fixed with paraformal-
dehyde, incubated for 15 min with DAPI, and then visua-
lized under fluorescent microscopy measuring emission at
460 nm with 360 nm excitation. The percentage of DAPI-
stained cells with apoptotic morphology (nuclear and
cytoplasmic condensation, nuclear fragmentation, mem-
brane blebbing, and apoptotic body formation) was eval-
uated by examining more than 400 cells/dish.
The presence of apoptotic cells was also examined by a
TUNEL reaction, which preferentially labels DNA strand
breaks generated during apoptosis (In Situ Cell Death
Detection Kit, Fluorescein; Roche).
2.10. Statistics
Data are the means  SD of at least two independent
experiments done in triplicate. Statistical significance was
estimated with Student’s t-test. A P value of <0.05 was
considered significant.
3. Results
3.1. NF-kB activation by C2- and C6- but not by
C16-ceramides
The tumor cell lines HCT116 (human colorectal ade-
nocarcinoma) and OVCAR-3 (human ovarian carcinoma)
were stably transfected with a plasmid encoding a mutated,
non-inducible IkBa inhibitor. We and others previously
reported that such an IkBa mutant can completely abolish
NF-kB activation by a number of stimulating agents, such
as TNF-a and anticancer drugs [27,29,30]. Indeed, after
TNF-a stimulation, we confirmed by EMSA that NF-kB
DNA-binding activity was strongly induced in control cells
but was inhibited markedly in mutated IkBa transfected
cells (data not shown).
HCT116 and OVCAR-3 control and transfected cells
were treated with three different ceramides (C2-, C6-, and
C16-ceramides) at 50 mM, and NF-kB DNA-binding activ-
ity was analyzed at different times after the treatment (1, 2,
4, 6, and 24 hr).
C2- and C6-ceramides induced NF-kB nuclear translo-
cation in OVCAR-3 cells (Fig. 1A and B) and in HCT116
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cells (data not shown), as demonstrated by EMSA per-
formed with nuclear extracts. The increase in NF-kB
DNA-binding activity was observed within 1 hr and per-
sisted for 6 hr. NF-kB induction by C2-ceramides was
abolished completely in IkBa-MT transfected cells (cf.
Fig. 1A). C16-ceramide did not show any activation of NF-
kB (data not shown).
Supershift experiments after treatment with ceramide
for 1 hr were performed with antibodies directed against
NF-kB proteins and demonstrated that the upper band was
displaced by both p50 and p65 antibodies and was formed
mainly of p50/p65 heterodimers (Fig. 1A and B; upper
arrow). The lower band reacted only with p50 antibodies
and likely corresponded to p50 homodimers (Fig. 1A and
B; lower arrow).
3.2. Cytotoxicity of ceramide in cancer cell lines
To determine whether stable inhibition of the NF-kB
transcription factor could increase the cytotoxic effect of
ceramide, control and mutated IkBa HCT116 and
OVCAR-3 cells were incubated in the presence of increas-
ing C2-, C6- and C16-ceramide concentrations, and cell
viability was measured after 24 and 48 hr (Fig. 2A and B).
Cell viability decreased in a concentration- and time-
dependent manner after C2- and C6-ceramide treatment.
C6-ceramide seemed to be somewhat more toxic than C2-
ceramide (Fig. 2A). C16-ceramide, on the other hand, did
not influence cell viability (Fig. 2A). This could be due to
its long carbon chain that prevents cellular uptake. This
result has been confirmed by flow cytometry using the
Annexin V/propidium iodide staining procedure (data not
shown).
As shown in Fig. 2B, IkBamutant-transfected OVCAR-
3 cells exhibited a cytotoxicity to C6-ceramide similar to
that of the control cells. No statistically significant differ-
ences were found (unpaired t-test; P > 0:05).
Under these conditions, NF-kB inhibition did not mod-
ify the cytotoxicity induced by either C6- or C2-ceramide
(data not shown).
3.3. Role of NF-kB in clonogenic survival after ceramide
treatment
To determine cell resistance to long-term ceramide
treatment and clonogenic survival of cells harboring
wild-type or mutated IkBa, we treated HCT116,
HCT116-MT, OVCAR-3, and OVCAR-3-MT cells with
C6-ceramide at different concentrations (10, 25, and
50 mM) for 48 hr and then incubated them with fresh
medium for 12 days. Under these conditions, no difference
was observed in the number and the size of the colonies
between control cells and cells expressing mutated IkBa
(data not shown).
Fig. 1. NF-kB activation by ceramide. EMSAs were performed on nuclear proteins isolated from untreated and treated cells. (A) OVCAR-3 cells were
treated with C2-ceramide (50 mM) for 1, 2, 4, and 6 hr, and then a supershifting experiment was performed after a 1-hr ceramide treatment. OVCAR-3-MT
cells were treated with C2-ceramide (50 mM) for 30 min and 1 hr. (B) OVCAR-3 cells were treated with C6-ceramide (50 mM) for 1, 2, 4, 6, and 24 hr, and
then a supershifting experiment was performed after 1 hr of ceramide treatment. The upper arrow indicates the specific NF-kB complex p50/p65, and the
lower arrow indicates the specific NF-kB complex p50/p50. Supershifted complexes are marked with an asterisk. All the experiments were performed in
triplicate.
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3.4. Role of ceramide in cell death
To investigate the nature of cell death (necrosis or
apoptosis) induced by ceramide, HCT116 and HCT116-
MT cells were treated with 50 mM C6-ceramide for various
times (4, 7, 16, and 24 hr) and then analyzed by flow
cytometry using the Annexin V/propidium iodide staining
procedure (Fig. 3A and B).
A kinetic chart showing the time on the x-axis and the
percentage (SD) on the y-axis for the Annexin Vþ
(AnVþ), the propidium iodide (PIþ), and the double-
positive populations (Fig. 3) demonstrated that the AnVþ
population first increased and then emptied into the AnVþ/
PIþ population. This confirms that apoptosis ends in a
secondary necrosis. The PIþ population only appeared
later and was constituted of isolated nuclei (data not
shown). As shown in Fig. 3, the percentage of apoptotic
HCT116 cells increased to 10% after 7 hr of treatment with
C6-ceramide, and the necrotic cell rate reached 10% after
24 hr of treatment. After 48 hr, most of the cells were dead
and were stained by both propidium iodide and Annexin V
(data not shown). No statistically significant differences
were found (unpaired t-test; P > 0:05) between apoptosis
and necrosis in HCT116 and HCT116 IkBa-MT cells.
3.5. Caspase activation with ceramide-induced
apoptosis
Morphological apoptotic changes, such as nuclear con-
densation and fragmentation without membrane disrup-
Fig. 2. Cell toxicity of ceramide. (A) HCT116 cells were seeded in 96-well plates at a concentration of 104/well and treated with C2-, C6-, or C16-ceramide at
different concentrations (5, 10, 25, 50, 75, and 100 mM) or with control medium for 24 hr. Cell viability was estimated with the colorimetric WST-1 test. The
data are means SD (N ¼ 3). (B) OVCAR and OVCAR-MT cells were seeded in 96-well plates at a concentration of 104/well and treated with C6-ceramide at
different concentrations (10, 25, 50, 75, and 100 mM) or with control medium for 48 hr. Cell viability was estimated with the colorimetric WST-1 test. The data
are means SD (N ¼ 12). No statistically significant differences were found between OVCAR and OVCAR-MT cells (unpaired t-test; P > 0:05).
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tion, were observed under light microscopy after staining
with DAPI. Moreover, TUNEL reaction labeled DNA
strand breaks generated by apoptosis after only 6 hr of
ceramide treatment.
Apoptosis is frequently associated with activation of a
family of cysteine aspartate proteases named caspases. To
determine whether ceramide treatment led to caspase
activation, caspase-3 and caspase-8 activities were ana-
lyzed in treated cells.
After treatment with C6-ceramide (50 mM, 24 hr), an
activation of caspase-3 (effector caspase) was observed in
HCT116 cells (Fig. 4A and B) and in OVCAR-3 cells (data
not shown). Caspase-3 activation was transient and the
maximum peaks were obtained after 24 hr of ceramide
treatment. No significant differences in caspase-3 activa-
tion were observed in control and IkBa-mutated HCT116
cells (Fig. 4A and B). Ceramide treatment induced weak
caspase-3 activation compared to daunomycin (2 mM),
which is a potent inducer of apoptosis in these cells [31].
Under the same experimental conditions, western blot-
ting with anti-caspase-8 antibody did not reveal any pro-
teolytic processing of caspase-8 (initiator caspase) within
24 hr of ceramide treatment (Fig. 5A).
To obtain additional evidence of caspase activation after
ceramide treatment, cells were examined for the caspase-
dependent cleavage of PARP protein. PARP cleavage was
detected by western blotting 30 hr after exposure of cells to
C6-ceramide, indicating the presence of functionally acti-
vated caspases (Fig. 5B).
3.6. Increased cytochrome c release in ceramide-treated
cells
We investigated the participation of the mitochondria in
ceramide-induced apoptosis by analysing the release of
cytochrome c from the mitochondria into the cytosol.
Cytosolic, mitochondria-free extracts from HCT116 cells
treated with 50 mM C6-ceramide for 16 and 24 hr showed
an important release of cytochrome c (Fig. 5C).
3.7. Increased cell survival with caspase inhibitors
HCT116 and HCT116-MT cells were pretreated for 1 hr
with the caspase inhibitor Z-VAD (cf. Fig. 6, condition 3)
and the caspase-3 inhibitor (cf. Fig. 6, condition 4) and then
were treated with C6-ceramide at 50 mM for 24 hr to
examine the role of activated caspases in ceramide-induced
cell death. The addition of the caspase inhibitors decreased
cell death by only 5–10%, which corresponds to the
percentage of apoptosis after 24 hr of treatment (cf. Fig. 3).
3.8. Role of ceramide in cell cycle arrest
After 16 hr of C6-ceramide treatment, the DNA content
was analysed by flow cytometry. The percentage of
HCT116 cells in G0/G1 did not change significantly
(41–45%) (Fig. 7A and B). The percentage of cells in S
phase decreased from 43 to 14%, and the percentage of
cells in G2/M increased from 16 to 42%. That can be
interpreted as a double block in G1 and G2, thus emptying
the S phase.
4. Discussion
Among the recognized bioactive molecules, sphingoli-
pid metabolites play important roles in signal transduction
and cell regulation [2,22]. A number of extracellular
agents, such as TNF-a, and chemotherapeutic agents acti-
vate sphingomyelinase, which generates ceramides from
membrane sphingomyelin. Ceramides were first shown to
Fig. 3. Cell necrosis and cell apoptosis by C6-ceramide. (A) HCT116 cells
were incubated with C6-ceramide (50 mM) for 4, 7, 16, and 24 hr. Cells
were analyzed by flow cytometry with Annexin V (AnV) and propidium
iodide (PI). All the experiments were performed in triplicate. Key: (&)
AnVþ/PIþ HCT116; (*) AnVþ HCT116; and (!) PIþ HCT116. (B)
HCT116-MT cells were incubated with C6-ceramide (50 mM) for 4, 7, 16,
and 24 hr. Cells were analyzed by flow cytometry with Annexin V (AnV)
and propidium iodide (PI). All the experiments were performed in
triplicate. Key: (&) AnVþ/PIþ HCT116-MT; (*) AnVþ HCT116-MT;
and (r) PIþ HCT116-MT. Values in both panels are presented as
means SD.
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be involved in cellular differentiation or cell cycle arrest
[5]. But, recently, ceramides were postulated to be second
messengers of apoptosis in some cell types [10]. The
outcome of ceramide signaling is cell-type dependent.
With respect to apoptosis, the activation of caspases is
interesting to study since these proteases are actively
involved in the execution phase of the apoptotic process.
However, it is not clear whether activation of this protease
family is dependent upon ceramide generation.
In our study, we showed that treatment of HCT116 and
OVCAR-3 cancer cells with exogenous C2- and C6-cer-
amides led to NF-kB activation, partial caspase-3 activa-
tion, and partial PARP cleavage. The caspase-3 activation
was transient, and the maximum peaks were obtained after
24 hr of ceramide treatment. This observation was con-
firmed by caspase-dependent cleavage of PARP protein
that was detected 30 hr after ceramide treatment. More-
over, the use of caspase inhibitors did increase cell viability
by 10–20%, confirming that caspase activation plays some
role in ceramide-induced apoptosis.
An increase of cytochrome c release into the cytoplasm
was observed in the HCT116 cells after ceramide treat-
ment. This suggests the participation of mitochondria in
ceramide-induced apoptosis. In our study, apoptosis was
also confirmed by flow cytometric analysis and cytochem-
ical staining.
Exogenous C16-ceramide had no effect on cell viability
and NF-kB activation, probably due do its long fatty acid
chain, which prevents its uptake into the cytoplasm. How-
ever, C16-ceramide is known to be an endogenous lipid
species, and it would be very interesting to follow its
variation after specific cell stresses using a very sensitive
and selective technique, such as tandem mass spectrometry
[32].
Fig. 4. Caspase-3 activation by ceramide. (A) HCT116 and HCT116-MT cells were treated with C6-ceramide (50 mM) for different times (6, 16, 24, 30, and
40 hr) or with control medium. Twenty micrograms of total cell lysates was separated on SDS–polyacrylamide gels, and immunoblotting was revealed with
an anti-caspase-3 antibody. The intact 32-kDa pro-caspase-3 and its 12-kDa cleavage product are shown. The experiments were performed in triplicate. (B)
Caspase-3 activity was also determined by a caspase-3 activity assay [the amount of release fluorescent product (coumarin) measuring emission at 460 nm
with 380 nm excitation]. HCT116 and HCT116-MT cells were treated with C6-ceramide (50 mM) for different times (16, 24, 30, 40, and 48 hr) or with
control medium. HCT116 cells treated with daunomycin (2 mM) for 24 hr were used as a positive control. Values are means SD; this experiment was
performed in triplicate.
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Several reports indicated that NF-kB constitutive activity
in cancer cells as well as NF-kB activation by TNF-a,
anticancer drugs, or ionizing radiation could protect cells
against apoptosis and would therefore favor cancer cell
survival and resistance to chemotherapy, probably by con-
trolling the expression of apoptosis inhibitors [24,30,33].
However, it is now recognized that NF-kB activity has a
variable effect on cell mortality, depending on cell type, the
stimulus, and the level of NF-kB activity. Thus, it was
interesting to determine the role of NF-kB in the toxicity of
exogenous ceramides. For this investigation, we used cell
lines expressing a mutated NF-kB inhibitor, which seques-
ters NF-kB in the cytoplasm. Although TNF-a and cera-
mides could efficiently induce NF-kB DNA-binding
activity in control untransfected cells, NF-kB inhibition
did not increase the cytotoxic effect of C2- and C6-cer-
amides. In our experimental conditions, NF-kB did not play
a role in the ceramide apoptotic pathway, suggesting that
other mechanisms are involved.
Conversely, it has been demonstrated that NF-kB acti-
vation can inhibit caspase activity through the transcription
of the c-iap gene [34]. The activation of NF-kB by
ceramide treatment could explain why caspase activation
is limited during ceramide-induced apoptosis. But this
hypothesis does not seem to be confirmed by the experi-
ments with cells expressing the mutated form of IkBa.
Concerning cell cycle arrest, our results indicate that C6-
ceramide induced a double block in G1 and G2, thus
emptying the S phase. Other investigators reported a G1
or S phase cycle arrest after ceramide exposure [26]. This
discrepancy supports growing evidence that significant
cell-type-specific differences exist in cell death pathways.
Fig. 5. (A) Lack of caspase-8 activation. HCT116 cells were untreated or
treated with C6-ceramide (50 mM) for 4, 6, 16, and 24 hr. Twenty
micrograms of total cell lysates was separated on SDS–polyacrylamide
gels, and immunoblotting was revealed with an anti-caspase-8 antibody.
The intact 55-kDa pro-caspase-8 and its 40-kDa cleavage product are
shown. (B) PARP cleavage. HCT116 cells were untreated or treated with
ceramide (50 mM) for 30 and 48 hr. We also performed a positive control
(c) with OVCAR-3-MT cells treated with TNF-a for 24 hr. Twenty
micrograms of total cell lysates were separated on SDS–polyacrylamide
gels, and immunoblotting was performed with an anti-PARP antibody.
The intact 116-kDa PARP and its 85-kDa cleavage product are indicated.
The arrow indicates the cleaved form of PARP. (C) Increase of
cytochrome c release. HCT116 cells were untreated or treated with
ceramide (50 mM) for 16 and 24 hr. Twenty micrograms of cytoplasmic
extract was subjected to SDS–PAGE, and immunoblotting was performed
with an anti-cytochrome c antibody. All the experiments were performed
in triplicate.
Fig. 6. Partial increase of cell survival with caspase inhibitors. HCT116 and HCT116-MT cells were seeded in 96-well plates at a concentration of 104/well
and were not treated (1), treated with C6-ceramide at 50 mM for 24 hr (2), pretreated for 1 hr with the caspase inhibitor Z-VAD and then treated with C6-
ceramide at 50 mM for 24 hr (3), or pretreated for 1 hr with the caspase-3 inhibitor and then treated with C6-ceramide at 50 mM for 24 hr (4). Cell viability
was estimated with the colorimetric WST-1 test. The data are means SD (N ¼ 3).
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An improved understanding of the role of ceramide in
tumor cell drug responses may facilitate the development
of novel strategies for new or established chemotherapeutic
agents. Indeed, in the treatment of cancer, suppression of
anti-apoptotic signals may increase the sensitivity of target
tissues to radiation or chemotherapy. Alternatively, activa-
tion of anti-apoptotic signals could prevent the inadvertent
death of normal tissue. Moreover, it has become clear that
tumor cells have developed strategies to reduce ceramide
elevations and attenuate its pro-apoptotic effect.
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